Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo-the POLESTAR trial.
Joris F OomsKristoff CornelisHarindra C WijeysunderaBert VandelooJan Van Der HeydenJan KovacDavid WoodAlbert ChanJoanna WykyrzykowskaLiesbeth RosseelMichael CunningtonFrank van der KleyBenno RensingMichiel VoskuilDavid Hildick-SmithNicolas M Van MieghemPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2024)
Early discharge after TAVI with the ACURATE valve is safe and feasible in selected patients. Rhythm monitoring and extended clinical observation protracted hospital stay.
Keyphrases
- transcatheter aortic valve implantation
- aortic stenosis
- aortic valve
- ejection fraction
- aortic valve replacement
- end stage renal disease
- transcatheter aortic valve replacement
- newly diagnosed
- chronic kidney disease
- healthcare
- clinical trial
- peritoneal dialysis
- atrial fibrillation
- prognostic factors
- mitral valve
- left ventricular
- phase ii
- randomized controlled trial
- heart rate
- blood pressure
- patient reported outcomes
- adverse drug
- double blind